Our drug development pipeline

Drugs currently under development

TrialSpark-Drug-Pipeline 2022-Dec

TrialSpark active clinical trials

Introducing Sprifermin to Knee Osteoarthritis Patients

We recognize the unmet need to prevent the worsening of your condition and are helping participants explore potential treatment options for knee OA.

Register to participate

TrialSpark drugs in the news

TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio

November 29, 2022

TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck and forms NewCo

January 10, 2022

Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis